Sort
4,870 grants matching “glp 1”
Novel PARS inhibitor for therapy of colitis
$857,140Inotek Pharmaceuticals Corporation · R44 · FY2002 · DK
Development of an engineered CCL20 protein as a lead therapeutic molecule for psoriasis
$856,782Chad Allen Koplinski · Xlock Biosciences, Llc · R44 · FY2020 · AR
Renal Therapeutic Angiogenesis Using the Novel Biologic ELP-VEGF
$856,297Gene Leflore Bidwell · Leflore Technologies, Llc · R42 · FY2024 · DK
AAV-mediated gene therapy for GM2-gangliodoses
$855,961Miguel S Esteves · Univ Of Massachusetts Med Sch Worcester · U01 · FY2010 · NS
AAV-mediated gene therapy for GM2-gangliodoses
$855,961Miguel S Esteves · Univ Of Massachusetts Med Sch Worcester · U01 · FY2010 · NS
Mild Hypothermia Catheter for Reperfusion Injury
$855,323Aditya Pandit · 3dt Holdings, Llc · R44 · FY2017 · HL
Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track)
$855,001Zhiyong Yang · Fzata, Inc. · R44 · FY2022 · DK
Development of Tumor and Immuno-Metabolism Based Small Molecule Therapeutics for Refractory Breast Cancer
$854,530Vincent Sandanayaka · Nirogyone Therapeutics, Llc · R44 · FY2021 · CA
Development of the RXR agonist IRX4204 to treat Multiple Sclerosis and other Immune related Diseases
$854,395Rosh Chandraratna · Io Therapeutics, Inc. · R44 · FY2016 · AI
Biomechatronics Device for Diagnosis/Therapy of Anorectal Disorders
$854,130William Combs · 3dt Holdings, Llc · R44 · FY2023 · DK
Core C - The University of Texas Medical Branch at Galveston
$852,988Thomas William Geisbert · Henry M. Jackson Fdn For The Adv Mil/Med · U19 · FY2020 · AI
Evaluation of a Novel Connexin-Based Peptide for the Treatment of Diabetic Wounds
$852,751Gautam Sudhir Ghatnekar · Xequel Bio, Inc. · SB1 · FY2017 · DK
Translational Research for Retinal Degeneration Therapies
$851,453Gustavo David Aguirre · University Of Pennsylvania · R01 · FY2011 · EY
Scientific Core - Compound Optimization and Prioritization.
$850,917Anna Upton · Global Alliance For Tb Drug Development · U19 · FY2022 · AI
SmartInsulin Stability, Process Development, Assay Validation and GMP Manufacturi
$850,859Todd C Zion · Smartcells, Inc. · R44 · FY2009 · DK
Translational Research for Retinal Degeneration Therapies
$850,749Gustavo David Aguirre · University Of Pennsylvania · R01 · FY2009 · EY
Translational Research for Retinal Degeneration Therapies
$850,051Gustavo David Aguirre · University Of Pennsylvania · R01 · FY2007 · EY
Bacteriophage virus-like particle vaccines for fentanyl and heroin overdose
$849,872Bryce C Chackerian · University Of New Mexico Health Scis Ctr · UH3 · FY2025 · DA
Bioabsorbable Magnesium (Mg) Implants for Craniomaxillofacial Surgical Systems
$848,603Stephen Lebeau · Nanomag, Llc · R44 · FY2017 · DE
AAV-mediated gene therapy for GM2-gangliodoses
$847,727Miguel S Esteves · Univ Of Massachusetts Med Sch Worcester · U01 · FY2012 · NS
IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis
$847,546Dominick Auci · Therapyx, Inc. · R44 · FY2021 · DK
AIManage using an AI-driven CDS and chatbot for the management of patients on incretin mimetic medications
$847,498Elizabeth Reid Stevens · New York University School Of Medicine · R01 · FY2025 · DK
Structural Analysis Of Candidate Genes For Type 2 Diabetes and Obesity
$847,201Leslie J Baier · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2022 · DK
Structural Analysis Of Candidate Genes For Type 2 Diabetes and Obesity
$846,151Leslie J Baier · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2017 · DK
Definitive Studies For Use Of Galantamine As A Pre-Treatment Countermeasure Again
$844,970Bill Basinger · Countervail Corporation · R44 · FY2014 · NS